Logo image
Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182
Journal article   Open access   Peer reviewed

Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182

Neil S Horowitz, Austin Miller, Bunja Rungruang, Scott D Richard, Noah Rodriguez, Michael A Bookman, Chad A Hamilton, Thomas C Krivak and G Larry Maxwell
Journal of clinical oncology, v 33(8), pp 937-943
10 Mar 2015
PMID: 25667285
url
https://doi.org/10.1200/jco.2014.56.3106View
Published, Version of Record (VoR)Open Access (License Unspecified) Open
url
https://doi.org/10.1200/JCO.2014.56.3106View
Published, Version of Record (VoR) Open

Abstract

Adult Aged Disease-Free Survival Female Gynecologic Surgical Procedures Humans Kaplan-Meier Estimate Middle Aged Multivariate Analysis Neoplasm, Residual Ovarian Neoplasms - surgery Ovarian Neoplasms - therapy Peritoneal Neoplasms - surgery Peritoneal Neoplasms - therapy Prognosis Time Factors Treatment Outcome
To examine the effects of disease burden, complex surgery, and residual disease (RD) status on progression-free (PFS) and overall survival (OS) in patients with advanced epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC) and complete surgical resection (R0) or < 1 cm of RD (MR) after surgical cytoreduction. Demographic, pathologic, surgical, and outcome data were collected from 2,655 patients with EOC or PPC enrolled onto the Gynecologic Oncology Group 182 study. The effects of disease distribution (disease score [DS]) and complexity of surgery (complexity score [CS]) on PFS and OS were assessed using the Kaplan-Meier method and multivariable regression analysis. Consistent with existing literature, patients with MR had worse prognosis than R0 patients (PFS, 15 v 29 months; P < .01; OS, 41 v 77 months; P < .01). Patients with the highest preoperative disease burden (DS high) had shorter PFS (15 v 23 or 34 months; P < .01) and OS (40 v 71 or 86 months; P < .01) compared with those with DS moderate or low, respectively. This relationship was maintained in the subset of R0 patients with PFS (18.3 v 33.2 months; DS moderate or low: P < .001) and OS (50.1 v 82.8 months; DS moderate or low: P < .001). After controlling for DS, RD, an interaction term for DS/CS, performance status, age, and cell type, CS was not an independent predictor of either PFS or OS. In this large multi-institutional sample, initial disease burden remained a significant prognostic indicator despite R0. Complex surgery does not seem to affect survival when accounting for other confounding influences, particularly RD.

Metrics

16 Record Views
218 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being
#5 Gender Equality

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
Web of Science research areas
Oncology
Logo image